Argenx M&A, AI giants in biopharma, catalyst scorecard — a BioCentury podcast

The $2B takeout of Forte, mapping AI moves in biopharma, and 1H26 clinical wins and losses

Argenx S.E., the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences Inc. will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal and put it in the context of a new cohort of large-cap companies increasingly active in biotech M&A.

The analysts also assess how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one another. Finally, they analyze the 1H26 clinical and regulatory catalyst scorecard, which therapies hit their milestones, which missed, and what’s next through year-end.